Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 514-523

  Lee, Mi Sook ^a   Kim, Hwang Phill ^a   Kim, Tae You ^a   Lee, Jung Weon ^a  

^a Seoul National University   (South Korea)

Author keywords

Drug resistance; EGFR; Epithelial mesenchymal transition; Lung cancer; Tetraspanin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRANSMEMBRANE 4 L SIX FAMILY MEMBER 5; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL INTERACTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOSOL; EPITHELIAL MESENCHYMAL TRANSITION; LUNG NON SMALL CELL CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84862820581     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.11.017     Document Type: Article

References (39)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G., Kwiatkowski D.J., Engelman J.A., Janne P.A. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
4. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
5. Suda K., Onozato R., Yatabe Y., Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival?. J. Thorac. Oncol. 2009, 4:1-4.
6. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 2009, 10:281-289.
7. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., Chiang A., Yang G., Ouerfelli O., Kris M.G., Ladanyi M., Miller V.A., Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 2006, 12:6494-6501.
8. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., Tenen D.G., Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007, 4:1669-1679. discussion 1680.
9. Guo A., Villen J., Kornhauser J., Lee K.A., Stokes M.P., Rikova K., Possemato A., Nardone J., Innocenti G., Wetzel R., Wang Y., MacNeill J., Mitchell J., Gygi S.P., Rush J., Polakiewicz R.D., Comb M.J. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:692-697.
10. Kim H.P., Han S.W., Kim S.H., Im S.A., Oh D.Y., Bang Y.J., Kim T.Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008, 7:607-615.
11. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.C., Miller V., Ladany M., Yang C.H., Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20932-20937.
12. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y.C., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X.J., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
13. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.
14. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65:9455-9462.
15. Rho J.K., Choi Y.J., Lee J.K., Ryoo B.-Y., Na I.I., Yang S.H., Kim C.H., Lee J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63:219-226.
16. Muschel R.J., Gal A. Tetraspanin in oncogenic epithelial-mesenchymal transition. J. Clin. Invest. 2008, 118:1347-1350.
17. Lee S.A., Lee S.Y., Cho I.H., Oh M.A., Kang E.S., Kim Y.B., Seo W.D., Choi S., Nam J.O., Tamamori-Adachi M., Kitajima S., Ye S.K., Kim S., Hwang Y.J., Kim I.S., Park K.H., Lee J.W. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. 2008, 118:1354-1366.
18. Kim H., Kang M., Lee S.A., Kwak T.K., Jung O., Lee H.J., Kim S.H., Lee J.W. TM4SF5 accelerates G1/S phase progression via cytosolic p27(Kip1) expression and RhoA activity. Biochim. Biophys. Acta 2010, 1803:975-982.
19. Muller-Pillasch F., Wallrapp C., Lacher U., Friess H., Buchler M., Adler G., Gress T.M. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 1998, 208:25-30.
20. Wright M.D., Ni J., Rudy G.B. The L6 membrane proteins - a new four-transmembrane superfamily. Protein Sci. 2000, 9:1594-1600.
21. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J. Cell Sci. 2001, 114:4143-4151.
22. Choi S., Lee S.A., Kwak T.K., Kim H.J., Lee M.J., Ye S.K., Kim S.H., Kim S., Lee J.W. Cooperation between integrin α5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 2009, 113:1845-1855.
23. Lee S.A., Kim Y.M., Kwak T.K., Kim H.J., Kim S., Kim S.H., Park K.H., Cho M., Lee J.W. The extracellular loop 2 of TM4SF5 inhibits integrin α2 on hepatocytes under collagen type I environment. Carcinogenesis 2009, 30:1872-1879.
24. Lee S.A., Kim T.Y., Kwak T.K., Kim H., Kim S., Lee H.J., Kim S.H., Park K.H., Kim H.J., Cho M., Lee J.W. Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis. J. Cell. Biochem. 2010, 111:59-66.
25. Stipp C.S., Kolesnikova T.V., Hemler M.E. Functional domains in tetraspanin proteins. Trends Biochem. Sci. 2003, 28:106-112.
26. Naldini L., Weidner K.M., Vigna E., Gaudino G., Bardelli A., Ponzetto C., Narsimhan R.P., Hartmann G., Zarnegar R., Michalopoulos G.K., et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991, 10:2867-2878.
27. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
28. Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004, 18:862-876.
29. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
30. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 2003, 13:65-70.
31. Yang X., Kovalenko O.V., Tang W., Claas C., Stipp C.S., Hemler M.E. Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J. Cell Biol. 2004, 167:1231-1240.
32. Yanez-Mo M., Barreiro O., Gordon-Alonso M., Sala-Valdes M., Sanchez-Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 2009, 19:434-446.
33. Lekishvili T., Fromm E., Mujoomdar M., Berditchevski F. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility. J. Cell Sci. 2008, 121:685-694.
34. Lee S.Y., Kim Y.T., Lee M.S., Kim Y.B., Chung E., Kim S., Lee J.W. Focal adhesion and actin organization by a cross-talk of TM4SF5 with integrin α2 are regulated by serum treatment. Exp. Cell Res. 2006, 312:2983-2999.
35. Richardson M.M., Jennings L.K., Zhang X.A. Tetraspanins and tumor progression. Clin. Exp. Metastasis 2011, 28:261-270.
36. Ke A.W., Shi G.M., Zhou J., Huang X.Y., Shi Y.H., Ding Z.B., Wang X.Y., Devbhandari R.P., Fan J. CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011, 140:1629-1641. e1615.
37. Desiderio M.A. Hepatocyte growth factor in invasive growth of carcinomas. Cell Mol. Life Sci. 2007, 64:1341-1354.
38. Thomson S., Petti F., Sujka-Kwok I., Mercado P., Bean J., Monaghan M., Seymour S.L., Argast G.M., Epstein D.M., Haley J.D. A systems view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metastasis 2011, 28:137-155.
39. Lee S.A., Ryu H.W., Kim Y.M., Choi S., Lee M.J., Kwak T.K., Kim H.J., Cho M., Park K.H., Lee J.W. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 2009, 49:1316-1325.